Skip to main content
SpringerLink
Log in

Present and Future Therapies for Chronic Hepatitis B

  • Chapter
  • First Online:
Hepatitis B Virus Infection

Part of the book series: Advances in Experimental Medicine and Biology ((AEMB,volume 1179))

Abstract

Chronic hepatitis B (CHB) remains the leading cause of liver-related morbidity and mortality across the world. If left untreated, approximately one-third of these patients will progress to severe end-stage liver diseases including liver failure, cirrhosis, and hepatocellular carcinoma (HCC). High level of serum HBV DNA is strongly associated with the development of liver failure, cirrhosis, and HCC. Therefore, antiviral therapy is crucial for the clinical management of CHB. Current antiviral drugs including nucleoside/nucleotide analogues (NAs) and interferon-α (IFN-α) can suppress HBV replication and reduce the progression of liver disease, thus improving the long-term outcomes of CHB patients. This chapter will discuss the standard and optimization antiviral therapies in treatment-naïve and treatment-experienced patients, as well as in the special populations. The up-to-date advances in the development of new anti-HBV agents will be also discussed. With the combination of the current antiviral drugs and the newly developed antiviral agents targeting the different steps of the viral life cycle or the newly developed agents modulating the host immune responses, the ultimate eradication of HBV will be achieved in the future.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 139.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 179.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 179.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. European Association for the Study of the Liver (2017) Electronic address eee, European Association for the Study of the L. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol 67(2):370–398

    Article  Google Scholar 

  2. Terrault NA, Bzowej NH, Chang KM, Hwang JP, Jonas MM, Murad MH et al (2016) AASLD guidelines for treatment of chronic hepatitis B. Hepatology (Baltimore, MD) 63(1):261–283

    Article  Google Scholar 

  3. Iloeje UH, Yang HI, Su J, Jen CL, You SL, Chen CJ et al (2006) Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology 130(3):678–686

    Article  PubMed  Google Scholar 

  4. Chen CF, Lee WC, Yang HI, Chang HC, Jen CL, Iloeje UH et al (2011) Changes in serum levels of HBV DNA and alanine aminotransferase determine risk for hepatocellular carcinoma. Gastroenterology 141(4).:1240–8, 8 e1–2

    Article  CAS  Google Scholar 

  5. Sinn DH, Lee J, Goo J, Kim K, Gwak GY, Paik YH et al (2015) Hepatocellular carcinoma risk in chronic hepatitis B virus-infected compensated cirrhosis patients with low viral load. Hepatology 62(3):694–701

    Article  CAS  PubMed  Google Scholar 

  6. Grossi G, Vigano M, Loglio A, Lampertico P (2017) Hepatitis B virus long-term impact of antiviral therapy nucleot(s)ide analogues (NUCs). Liver Int 37(Suppl 1):45–51

    Article  CAS  PubMed  Google Scholar 

  7. Wu CY, Lin JT, Ho HJ, Su CW, Lee TY, Wang SY et al (2014) Association of nucleos(t)ide analogue therapy with reduced risk of hepatocellular carcinoma in patients with chronic hepatitis B: a nationwide cohort study. Gastroenterology 147(1):143–51 e5

    Article  CAS  PubMed  Google Scholar 

  8. Liaw YF, Sung JJ, Chow WC, Farrell G, Lee CZ, Yuen H et al (2004) Lamivudine for patients with chronic hepatitis B and advanced liver disease. New Engl J Med 351(15):1521–1531

    Article  CAS  PubMed  Google Scholar 

  9. Chen CJ, Yang HI, Su J, Jen CL, You SL, Lu SN et al (2006) Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 295(1):65–73

    Article  CAS  PubMed  Google Scholar 

  10. Seto WK, Hui AJ, Wong VW, Wong GL, Liu KS, Lai CL et al (2015) Treatment cessation of entecavir in Asian patients with hepatitis B e antigen negative chronic hepatitis B: a multicentre prospective study. Gut 64(4):667–672

    Article  CAS  PubMed  Google Scholar 

  11. Terrault NA, Lok ASF, McMahon BJ, Chang KM, Hwang JP, Jonas MM et al (2018) Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology (Baltimore, MD) 67(4):1560–1599

    Article  Google Scholar 

  12. Sarin SK, Kumar M, Lau GK, Abbas Z, Chan HL, Chen CJ et al (2016) Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. Hepatol Int 10(1):1–98

    Article  CAS  PubMed  Google Scholar 

  13. EASL (2017) 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol 67(2):370–398

    Article  Google Scholar 

  14. Zhang J, Wen XY, Gao RP (2019) Hepatitis B virus-related liver cirrhosis complicated with dermatomyositis: a case report. World J Clin Cases 7(10):1206–1212

    Article  PubMed  PubMed Central  Google Scholar 

  15. Nemoto M, Nishioka K, Fukuoka J, Aoshima M (2019) Hepatitis B virus-associated vasculitis: a case report of multiple cavitary masses in the lung mimicking granulomatous polyangiitis. Intern Med. https://doi.org/10.2169/internalmedicine.3012-19

    Article  PubMed  PubMed Central  Google Scholar 

  16. Wong GL (2018) Management of chronic hepatitis B patients in immunetolerant phase: what latest guidelines recommend. Clin Mol Hepatol 24(2):108–113

    Article  PubMed  PubMed Central  Google Scholar 

  17. Hou J, Wang G, Wang F, Cheng J, Ren H, Zhuang H et al (2017) Guideline of prevention and treatment for chronic hepatitis B (2015 update). J Clin Transl Hepatol 5(4):297–318

    Article  PubMed  PubMed Central  Google Scholar 

  18. Menendez-Arias L, Alvarez M, Pacheco B (2014) Nucleoside/nucleotide analog inhibitors of hepatitis B virus polymerase: mechanism of action and resistance. Curr Opin Virol 8:1–9

    Article  CAS  PubMed  Google Scholar 

  19. Koumbi L (2015) Current and future antiviral drug therapies of hepatitis B chronic infection. World J Hepatol 7(8):1030–1040

    Article  PubMed  PubMed Central  Google Scholar 

  20. Liaw YF, Leung NW, Chang TT, Guan R, Tai DI, Ng KY et al (2000) Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. Gastroenterology 119(1):172–180

    Article  CAS  PubMed  Google Scholar 

  21. Ayoub WS, Keeffe EB (2011) Review article: current antiviral therapy of chronic hepatitis B. Aliment Pharmacol Ther 34(10):1145–1158

    Article  CAS  PubMed  Google Scholar 

  22. Marcellin P, Chang TT, Lim SG, Tong MJ, Sievert W, Shiffman ML et al (2003) Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med 348(9):808–816

    Article  CAS  PubMed  Google Scholar 

  23. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, Chang TT, Kitis G, Rizzetto M et al (2003) Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. N Engl J Med 348(9):800–807

    Article  CAS  PubMed  Google Scholar 

  24. Salpini R, Alteri C, Cento V, Pollicita M, Micheli V, Gubertini G et al (2013) Snapshot on drug-resistance rate and profiles in patients with chronic hepatitis B receiving nucleos(t)ide analogues in clinical practice. J Med Virol 85(6):996–1004

    Article  CAS  PubMed  Google Scholar 

  25. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, Chang TT, Kitis G, Rizzetto M et al (2006) Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. Gastroenterology 131(6):1743–1751

    Article  CAS  PubMed  Google Scholar 

  26. Liaw YF, Gane E, Leung N, Zeuzem S, Wang Y, Lai CL et al (2009) 2-Year GLOBE trial results: telbivudine Is superior to lamivudine in patients with chronic hepatitis B. Gastroenterology 136(2):486–495

    Article  CAS  PubMed  Google Scholar 

  27. Han GR, Cao MK, Zhao W, Jiang HX, Wang CM, Bai SF et al (2011) A prospective and open-label study for the efficacy and safety of telbivudine in pregnancy for the prevention of perinatal transmission of hepatitis B virus infection. J Hepatol 55(6):1215–1221

    Article  CAS  PubMed  Google Scholar 

  28. Han GR, Jiang HX, Yue X, Ding Y, Wang CM, Wang GJ et al (2015) Efficacy and safety of telbivudine treatment: an open-label, prospective study in pregnant women for the prevention of perinatal transmission of hepatitis B virus infection. J Viral Hepat 22(9):754–762

    Article  CAS  PubMed  Google Scholar 

  29. Marcellin P, Chang TT, Lim SG, Sievert W, Tong M, Arterburn S et al (2008) Long-term efficacy and safety of adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. Hepatology (Baltimore, MD) 48(3):750–758

    Article  CAS  Google Scholar 

  30. Seto WK, Lai CL, Fung J, Wong DK, Yuen JC, Hung IF et al (2011) Significance of HBV DNA levels at 12 weeks of telbivudine treatment and the 3 years treatment outcome. J Hepatol 55(3):522–528

    Article  CAS  PubMed  Google Scholar 

  31. Kim KH, Kim ND, Seong BL (2010) Discovery and development of anti-HBV agents and their resistance. Molecules 15(9):5878–5908

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Tenney DJ, Levine SM, Rose RE, Walsh AW, Weinheimer SP, Discotto L et al (2004) Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to Lamivudine. Antimicrob Agents Chemother 48(9):3498–3507

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  33. Van Rompay KK, Durand-Gasselin L, Brignolo LL, Ray AS, Abel K, Cihlar T et al (2008) Chronic administration of tenofovir to rhesus macaques from infancy through adulthood and pregnancy: summary of pharmacokinetics and biological and virological effects. Antimicrob Agents Chemother 52(9):3144–3160

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  34. Verhelst D, Monge M, Meynard JL, Fouqueray B, Mougenot B, Girard PM et al (2002) Fanconi syndrome and renal failure induced by tenofovir: a first case report. Am J Kidney Dis 40(6):1331–1333

    Article  PubMed  Google Scholar 

  35. Magalhaes-Costa P, Matos L, Barreiro P, Chagas C (2015) Fanconi syndrome and chronic renal failure in a chronic hepatitis B monoinfected patient treated with tenofovir. Rev Esp Enferm Dig 107(8):512–514

    PubMed  Google Scholar 

  36. Hsu YC, Wei MT, Nguyen MH (2017) Tenofovir alafenamide as compared to tenofovir disoproxil fumarate in the management of chronic hepatitis B with recent trends in patient demographics. Expert Rev Gastroenterol Hepatol 11(11):999–1008

    Article  CAS  PubMed  Google Scholar 

  37. Yang HC, Kao JH (2014) Persistence of hepatitis B virus covalently closed circular DNA in hepatocytes: molecular mechanisms and clinical significance. Emerg Microb Infect 3(9):e64

    CAS  Google Scholar 

  38. Dill MT, Makowska Z, Trincucci G, Gruber AJ, Vogt JE, Filipowicz M et al (2014) Pegylated IFN-alpha regulates hepatic gene expression through transient Jak/STAT activation. J Clin Invest 124(4):1568–1581

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  39. Chang TT, Gish RG, de Man R, Gadano A, Sollano J, Chao YC et al (2006) A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med 354(10):1001–1010

    Article  CAS  PubMed  Google Scholar 

  40. Lai CL, Shouval D, Lok AS, Chang TT, Cheinquer H, Goodman Z et al (2006) Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med 354(10):1011–1020

    Article  CAS  PubMed  Google Scholar 

  41. Arends P, Sonneveld MJ, Zoutendijk R, Carey I, Brown A, Fasano M et al (2015) Entecavir treatment does not eliminate the risk of hepatocellular carcinoma in chronic hepatitis B: limited role for risk scores in Caucasians. Gut 64(8):1289–1295

    Article  CAS  PubMed  Google Scholar 

  42. Luo J, Li X, Wu Y, Lin G, Pang Y, Zhang X et al (2013) Efficacy of entecavir treatment for up to 5 years in nucleos(t)ide-naive chronic hepatitis B patients in real life. Int J Med Sci 10(4):427–433

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  43. Maklad S, Reyad EM, William EA, Abouzeid A (2018) Efficacy and safety of entecavir 0.5 mg in treating naive chronic hepatitis B virus patients in Egypt: five years of real life experience. Gastroenterol Res 11(2):138–144

    Article  CAS  Google Scholar 

  44. Marcellin P, Heathcote EJ, Buti M, Gane E, de Man RA, Krastev Z et al (2008) Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N Engl J Med 359(23):2442–2455

    Article  CAS  PubMed  Google Scholar 

  45. Marcellin P, Zoulim F, Hezode C, Causse X, Roche B, Truchi R et al (2016) Effectiveness and safety of tenofovir disoproxil fumarate in chronic hepatitis B: a 3-year, prospective, real-world study in France. Dig Dis Sci 61(10):3072–3083

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  46. Buti M, Gane E, Seto WK, Chan HL, Chuang WL, Stepanova T et al (2016) Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial. Lancet Gastroenterol Hepatol 1(3):196–206

    Article  PubMed  Google Scholar 

  47. Agarwal K, Brunetto M, Seto WK, Lim YS, Fung S, Marcellin P et al (2018) 96 weeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus infection. J Hepatol 68(4):672–681

    Article  CAS  PubMed  Google Scholar 

  48. Nguyen NH, Trinh HN, Nguyen TT, Do ST, Tran P, Nguyen HA et al (2015) Safety and efficacy of entecavir in adefovir-experienced patients. J Gastroenterol Hepatol 30(1):43–50

    Article  CAS  PubMed  Google Scholar 

  49. Zoulim F, Locarnini S (2009) Hepatitis B virus resistance to nucleos(t)ide analogues. Gastroenterology 137(5):1593–608 e1-2

    Article  CAS  PubMed  Google Scholar 

  50. Tenney DJ, Rose RE, Baldick CJ, Pokornowski KA, Eggers BJ, Fang J et al (2009) Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naive patients is rare through 5 years of therapy. Hepatology 49(5):1503–1514

    Article  CAS  PubMed  Google Scholar 

  51. Deng XL, Li QL, Guo JJ (2013) Dynamics of lamivudine-resistant hepatitis B virus strains in patients with entecavir rescue therapy. Virus Genes 47(1):1–9

    Article  CAS  PubMed  Google Scholar 

  52. Yuen MF, Lai CL (2011) Treatment of chronic hepatitis B: evolution over two decades. J Gastroenterol Hepatol 26(Suppl 1):138–143

    Article  PubMed  Google Scholar 

  53. Petersen J, Heyne R, Mauss S, Schlaak J, Schiffelholz W, Eisenbach C et al (2016) Effectiveness and safety of tenofovir disoproxil fumarate in chronic hepatitis B: A 3-year prospective field practice study in Germany. Dig Dis Sci 61(10):3061–3071

    Article  CAS  PubMed  Google Scholar 

  54. Chung GE, Cho EJ, Lee JH, Yoo JJ, Lee M, Cho Y et al (2017) Tenofovir has inferior efficacy in adefovir-experienced chronic hepatitis B patients compared to nucleos(t)ide-naive patients. Clin Mol Hepatol 23(1):66–73

    Article  PubMed  PubMed Central  Google Scholar 

  55. Park JY, Kim CW, Bae SH, Jung KS, Kim HY, Yoon SK et al (2016) Entecavir plus tenofovir combination therapy in patients with multidrug-resistant chronic hepatitis B: results of a multicentre, prospective study. Liver Int 36(8):1108–1115

    Article  CAS  PubMed  Google Scholar 

  56. Lee YB, Lee JH, Lee DH, Cho H, Ahn H, Choi WM et al (2014) Efficacy of entecavir-tenofovir combination therapy for chronic hepatitis B patients with multidrug-resistant strains. Antimicrob Agents Chemother 58(11):6710–6716

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  57. Konerman MA, Lok AS (2016) Interferon treatment for hepatitis B. Clin Liver Dis 20(4):645–665

    Article  PubMed  Google Scholar 

  58. European Association for the Study of the L (2012) EASL clinical practice guidelines: management of chronic hepatitis B virus infection. J Hepatol 57(1):167–185

    Article  Google Scholar 

  59. Lau GK, Piratvisuth T, Luo KX, Marcellin P, Thongsawat S, Cooksley G et al (2005) Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med 352(26):2682–2695

    Article  CAS  PubMed  Google Scholar 

  60. Marcellin P, Lau GK, Bonino F, Farci P, Hadziyannis S, Jin R et al (2004) Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N Engl J Med 351(12):1206–1217

    Article  CAS  PubMed  Google Scholar 

  61. Liaw YF, Kao JH, Piratvisuth T, Chan HL, Chien RN, Liu CJ et al (2012) Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update. Hepatol Int 6(3):531–561

    Article  PubMed  Google Scholar 

  62. Li SY, Li H, Xiong YL, Liu F, Peng ML, Zhang DZ et al (2017) Peginterferon is preferable to entecavir for prevention of unfavourable events in patients with HBeAg-positive chronic hepatitis B: a five-year observational cohort study. J Viral Hepat 24(Suppl 1):12–20

    Article  CAS  PubMed  Google Scholar 

  63. Stelma F, van der Ree MH, Jansen L, Peters MW, Janssen HLA, Zaaijer HL et al (2017) HBsAg loss after peginterferon-nucleotide combination treatment in chronic hepatitis B patients: 5 years of follow-up. J Viral Hepat 24(12):1107–1113

    Article  CAS  PubMed  Google Scholar 

  64. Marcellin P, Wursthorn K, Wedemeyer H, Chuang WL, Lau G, Avila C et al (2015) Telbivudine plus pegylated interferon alfa-2a in a randomized study in chronic hepatitis B is associated with an unexpected high rate of peripheral neuropathy. J Hepatol 62(1):41–47

    Article  CAS  PubMed  Google Scholar 

  65. Marcellin P, Ahn SH, Chuang WL, Hui AJ, Tabak F, Mehta R et al (2016) Predictors of response to tenofovir disoproxil fumarate plus peginterferon alfa-2a combination therapy for chronic hepatitis B. Aliment Pharmacol Ther 44(9):957–966

    Article  CAS  PubMed  Google Scholar 

  66. Ahn SH, Marcellin P, Ma X, Caruntu FA, Tak WY, Elkhashab M et al (2018) Hepatitis B surface antigen loss with tenofovir disoproxil fumarate plus peginterferon alfa-2a: week 120 analysis. Dig Dis Sci 63(12):3487–3497

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  67. Marcellin P, Ahn SH, Ma X, Caruntu FA, Tak WY, Elkashab M et al (2016) Combination of tenofovir disoproxil fumarate and peginterferon alpha-2a increases loss of hepatitis B surface antigen in patients with chronic hepatitis B. Gastroenterology 150(1):134–44 e10

    Article  CAS  PubMed  Google Scholar 

  68. de Niet A, Jansen L, Stelma F, Willemse SB, Kuiken SD, Weijer S et al (2017) Peg-interferon plus nucleotide analogue treatment versus no treatment in patients with chronic hepatitis B with a low viral load: a randomised controlled, open-label trial. Lancet Gastroenterol Hepatol 2(8):576–584

    Article  PubMed  Google Scholar 

  69. Bourliere M, Rabiega P, Ganne-Carrie N, Serfaty L, Marcellin P, Barthe Y et al (2017) Effect on HBs antigen clearance of addition of pegylated interferon alfa-2a to nucleos(t)ide analogue therapy versus nucleos(t)ide analogue therapy alone in patients with HBe antigen-negative chronic hepatitis B and sustained undetectable plasma hepatitis B virus DNA: a randomised, controlled, open-label trial. Lancet Gastroenterol Hepatol 2(3):177–188

    Article  PubMed  Google Scholar 

  70. Ning Q, Han M, Sun Y, Jiang J, Tan D, Hou J et al (2014) Switching from entecavir to PegIFN alfa-2a in patients with HBeAg-positive chronic hepatitis B: a randomised open-label trial (OSST trial). J Hepatol 61(4):777–784

    Article  CAS  PubMed  Google Scholar 

  71. Hu P, Shang J, Zhang W, Gong G, Li Y, Chen X et al (2018) HBsAg loss with Peg-interferon alfa-2a in hepatitis B patients with partial response to nucleos(t)ide analog: new switch study. J Clin Transl Hepatol 6(1):25–34

    PubMed  PubMed Central  Google Scholar 

  72. Brouwer WP, Xie Q, Sonneveld MJ, Zhang N, Zhang Q, Tabak F et al (2015) Adding pegylated interferon to entecavir for hepatitis B e antigen-positive chronic hepatitis B: a multicenter randomized trial (ARES study). Hepatology (Baltimore, MD) 61(5):1512–1522

    Article  CAS  Google Scholar 

  73. van Campenhout MJH, Brouwer WP, Xie Q, Guo S, Chi H, Qi X et al (2019) Long-term follow-up of patients treated with entecavir and peginterferon add-on therapy for HBeAg-positive chronic hepatitis B infection: ARES long-term follow-up. J Viral Hepat 26(1):109–117

    Article  CAS  PubMed  Google Scholar 

  74. Kim CH, Um SH, Seo YS, Jung JY, Kim JD, Yim HJ et al (2012) Prognosis of hepatitis B-related liver cirrhosis in the era of oral nucleos(t)ide analog antiviral agents. J Gastroenterol Hepatol 27(10):1589–1595

    Article  CAS  PubMed  Google Scholar 

  75. Shin SK, Kim JH, Park H, Kwon OS, Lee HJ, Yeon JE et al (2015) Improvement of liver function and non-invasive fibrosis markers in hepatitis B virus-associated cirrhosis: 2 years of entecavir treatment. J Gastroenterol Hepatol 30(12):1775–1781

    Article  CAS  PubMed  Google Scholar 

  76. Marcellin P, Gane E, Buti M, Afdhal N, Sievert W, Jacobson IM et al (2013) Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study. Lancet 381(9865):468–475

    Article  CAS  PubMed  Google Scholar 

  77. Shim JH, Lee HC, Kim KM, Lim YS, Chung YH, Lee YS et al (2010) Efficacy of entecavir in treatment-naive patients with hepatitis B virus-related decompensated cirrhosis. J Hepatol 52(2):176–182

    Article  CAS  PubMed  Google Scholar 

  78. Lee SK, Song MJ, Kim SH, Lee BS, Lee TH, Kang YW et al (2017) Safety and efficacy of tenofovir in chronic hepatitis B-related decompensated cirrhosis. World J Gastroenterol 23(13):2396–2403

    Article  PubMed  PubMed Central  Google Scholar 

  79. Papatheodoridis GV, Idilman R, Dalekos GN, Buti M, Chi H, van Boemmel F et al (2017) The risk of hepatocellular carcinoma decreases after the first 5 years of entecavir or tenofovir in Caucasians with chronic hepatitis B. Hepatology 66(5):1444–1453

    Article  CAS  PubMed  Google Scholar 

  80. Wong GL, Chan HL, Mak CW, Lee SK, Ip ZM, Lam AT et al (2013) Entecavir treatment reduces hepatic events and deaths in chronic hepatitis B patients with liver cirrhosis. Hepatology 58(5):1537–1547

    Article  CAS  PubMed  Google Scholar 

  81. Shim JJ, Oh CH, Kim JW, Lee CK, Kim BH (2017) Liver cirrhosis stages and the incidence of hepatocellular carcinoma in chronic hepatitis B patients receiving antiviral therapy. Scand J Gastroenterol 52(9):1029–1036

    PubMed  Google Scholar 

  82. Yang Y, Wen F, Li J, Zhang P, Yan W, Hao P et al (2015) A high baseline HBV load and antiviral therapy affect the survival of patients with advanced HBV-related HCC treated with sorafenib. Liver Int 35(9):2147–2154

    Article  CAS  PubMed  Google Scholar 

  83. Dan JQ, Zhang YJ, Huang JT, Chen MS, Gao HJ, Peng ZW et al (2013) Hepatitis B virus reactivation after radiofrequency ablation or hepatic resection for HBV-related small hepatocellular carcinoma: a retrospective study. Eur J Surg Oncol 39(8):865–872

    Article  PubMed  Google Scholar 

  84. Zhang H, Zhou Y, Yuan G, Zhou G, Yang D, Zhou Y (2015) Antiviral therapy improves the survival rate and decreases recurrences and fatalities in liver cancer patients following curative resection: a meta-analysis. Mol Clin Oncol 3(6):1239–1247

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  85. Fontana RJ, Ellerbe C, Durkalski VE, Rangnekar A, Reddy RK, Stravitz T et al (2015) Two-year outcomes in initial survivors with acute liver failure: results from a prospective, multicentre study. Liver Int 35(2):370–380

    Article  PubMed  Google Scholar 

  86. Chinese Society of Hepatology CMA, Chinese Society of Infectious Diseases CMA, Hou JL, lai W (2015) The guideline of prevention and treatment for chronic hepatitis B: a 2015 update. Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology 23(12):888–905

    Google Scholar 

  87. Zhang X, Liu L, Zhang M, Gao S, Du Y, An Y et al (2015) The efficacy and safety of entecavir in patients with chronic hepatitis B- associated liver failure: a meta-analysis. Ann Hepatol 14(2):150–160

    Article  CAS  PubMed  Google Scholar 

  88. Wan YM, Li YH, Xu ZY, Wu HM, Xu Y, Wu XN et al (2019) Tenofovir versus entecavir for the treatment of acute-on-chronic liver failure due to reactivation of chronic hepatitis B with genotypes B and C. J Clin Gastroenterol 53(4):e171–e1e7

    Article  CAS  PubMed  Google Scholar 

  89. Yuen MF (2015) Anti-viral therapy in hepatitis B virus reactivation with acute-on-chronic liver failure. Hepatol Int 9(3):373–377

    Article  PubMed  Google Scholar 

  90. Ishigami M, Ogura Y, Hirooka Y, Goto H (2015) Change of strategies and future perspectives against hepatitis B virus recurrence after liver transplantation. World J Gastroenterol 21(36):10290–10298

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  91. Marzano A, Gaia S, Ghisetti V, Carenzi S, Premoli A, Debernardi-Venon W et al (2005) Viral load at the time of liver transplantation and risk of hepatitis B virus recurrence. Liver Trans 11(4):402–409

    Article  Google Scholar 

  92. Protzer-Knolle U, Naumann U, Bartenschlager R, Berg T, Hopf U, Meyer zum Buschenfelde KH et al (1998) Hepatitis B virus with antigenically altered hepatitis B surface antigen is selected by high-dose hepatitis B immune globulin after liver transplantation. Hepatology 27(1):254–263

    Article  CAS  PubMed  Google Scholar 

  93. European Association for the Study of the Liver (2016) Electronic address eee. EASL Clinical Practice Guidelines: liver transplantation. J Hepatol 64(2):433–485

    Article  Google Scholar 

  94. Radhakrishnan K, Chi A, Quan DJ, Roberts JP, Terrault NA (2017) Short course of postoperative hepatitis B immunoglobulin plus antivirals prevents reinfection of liver transplant recipients. Transplantation 101(9):2079–2082

    Article  CAS  PubMed  Google Scholar 

  95. Cholongitas E, Goulis I, Antoniadis N, Fouzas I, Imvrios G, Papanikolaou V et al (2014) New nucleos(t)ide analogue monoprophylaxis after cessation of hepatitis B immunoglobulin is effective against hepatitis B recurrence. Transpl Int 27(10):1022–1028

    Article  CAS  PubMed  Google Scholar 

  96. Fung J, Wong T, Chok K, Chan A, Cheung TT, Dai JW et al (2017) Long-term outcomes of entecavir monotherapy for chronic hepatitis B after liver transplantation: results up to 8 years. Hepatology 66(4):1036–1044

    Article  CAS  PubMed  Google Scholar 

  97. Xu X, Chen J, Wei Q, Liu ZK, Yang Z, Zhang M et al (2019) Clinical practice guidelines on liver transplantation for hepatocellular carcinoma in China (2018 edition). Hepatobiliary Pancreat Dis Int 18(4):307–312

    Article  PubMed  Google Scholar 

  98. Roche B, Samuel D (2011) The difficulties of managing severe hepatitis B virus reactivation. Liv Int 31(Suppl 1):104–110

    Article  Google Scholar 

  99. Hoofnagle JH (2009) Reactivation of hepatitis B. Hepatology 49(5 Suppl):S156–S165

    Article  CAS  PubMed  Google Scholar 

  100. Bessone F, Dirchwolf M (2016) Management of hepatitis B reactivation in immunosuppressed patients: an update on current recommendations. World J Hepatol 8(8):385–394

    Article  PubMed  PubMed Central  Google Scholar 

  101. Hsu C, Tsou HH, Lin SJ, Wang MC, Yao M, Hwang WL et al (2014) Chemotherapy-induced hepatitis B reactivation in lymphoma patients with resolved HBV infection: a prospective study. Hepatology 59(6):2092–2100

    Article  CAS  PubMed  Google Scholar 

  102. WHO (2017) Global hepatitis report, 2017. World Health Organization, Geneva

    Google Scholar 

  103. Indolfi GEP, Dusheiko G, Siberry G, Chang MH, Thorne C et al (2019) Hepatitis B virus infection in children and adolescents. Lancet Gastroenterol Hepatol

    Google Scholar 

  104. Sokal EM, Paganelli M, Wirth S, Socha P, Vajro P, Lacaille F et al (2013) Management of chronic hepatitis B in childhood: ESPGHAN clinical practice guidelines: consensus of an expert panel on behalf of the European Society of Pediatric Gastroenterology, Hepatology and Nutrition. J Hepatol 59(4):814–829

    Article  PubMed  Google Scholar 

  105. Takano T, Tajiri H, Etani Y, Miyoshi Y, Tanaka Y, Brooks S (2015) Natural history of chronic hepatitis B virus infection in childhood and efficacy of interferon therapy. Scand J Gastroenterol 50(7):892–899

    Article  CAS  PubMed  Google Scholar 

  106. Sokal EM, Conjeevaram HS, Roberts EA, Alvarez F, Bern EM, Goyens P et al (1998) Interferon alfa therapy for chronic hepatitis B in children: a multinational randomized controlled trial. Gastroenterology 114(5):988–995

    Article  CAS  PubMed  Google Scholar 

  107. Kasirga E (2015) Lamivudine resistance in children with chronic hepatitis B. World J Hepatol 7(6):896–902

    Article  PubMed  PubMed Central  Google Scholar 

  108. Pawlowska M, Domagalski K, Smok B, Rajewski P, Wietlicka-Piszcz M, Halota W et al (2016) Continuous up to 4 years entecavir treatment of HBV-infected adolescents – a longitudinal study in real life. PLoS One 11(9):e0163691

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  109. Murray KF, Szenborn L, Wysocki J, Rossi S, Corsa AC, Dinh P et al (2012) Randomized, placebo-controlled trial of tenofovir disoproxil fumarate in adolescents with chronic hepatitis B. Hepatology 56(6):2018–2026

    Article  CAS  PubMed  Google Scholar 

  110. Zhou K, Terrault N (2017) Management of hepatitis B in special populations. Best Pract Res Clin Gastroenterol 31(3):311–320

    Article  PubMed  PubMed Central  Google Scholar 

  111. Xu WM, Cui YT, Wang L, Yang H, Liang ZQ, Li XM et al (2009) Lamivudine in late pregnancy to prevent perinatal transmission of hepatitis B virus infection: a multicentre, randomized, double-blind, placebo-controlled study. J Viral Hepat 16(2):94–103

    Article  PubMed  Google Scholar 

  112. Pan CQ, Han GR, Jiang HX, Zhao W, Cao MK, Wang CM et al (2012) Telbivudine prevents vertical transmission from HBeAg-positive women with chronic hepatitis B. Clin Gastroenterol Hepatol 10(5):520–526

    Article  CAS  PubMed  Google Scholar 

  113. Lin Y, Liu Y, Ding G, Touqui L, Wang W, Xu N et al (2018) Efficacy of tenofovir in preventing perinatal transmission of HBV infection in pregnant women with high viral loads. Sci Rep 8(1):15514

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  114. Yi W, Pan CQ, Hao J, Hu Y, Liu M, Li L et al (2014) Risk of vertical transmission of hepatitis B after amniocentesis in HBs antigen-positive mothers. J Hepatol 60(3):523–529

    Article  CAS  PubMed  Google Scholar 

  115. Wu Q, Huang H, Sun X, Pan M, He Y, Tan S et al (2015) Telbivudine prevents vertical transmission of hepatitis B virus from women with high viral loads: a prospective long-term study. Clin Gastroenterol Hepatol 13(6):1170–1176

    Article  CAS  PubMed  Google Scholar 

  116. Pan CQ, Duan Z, Dai E, Zhang S, Han G, Wang Y et al (2016) Tenofovir to prevent hepatitis B transmission in mothers with high viral load. N Engl J Med 374(24):2324–2334

    Article  CAS  PubMed  Google Scholar 

  117. Wang M, Bian Q, Zhu Y, Pang Q, Chang L, Li R et al (2019) Real-world study of tenofovir disoproxil fumarate to prevent hepatitis B transmission in mothers with high viral load. Aliment Pharmacol Ther 49(2):211–217

    Article  CAS  PubMed  Google Scholar 

  118. Zampino R, Pisaturo MA, Cirillo G, Marrone A, Macera M, Rinaldi L et al (2015) Hepatocellular carcinoma in chronic HBV-HCV co-infection is correlated to fibrosis and disease duration. Ann Hepatol 14(1):75–82

    Article  CAS  PubMed  Google Scholar 

  119. Pol S, Haour G, Fontaine H, Dorival C, Petrov-Sanchez V, Bourliere M et al (2017) The negative impact of HBV/HCV coinfection on cirrhosis and its consequences. Aliment Pharmacol Ther 46(11–12):1054–1060

    Article  CAS  PubMed  Google Scholar 

  120. Holmes JA, Yu ML, Chung RT (2017) Hepatitis B reactivation during or after direct acting antiviral therapy – implication for susceptible individuals. Expert Opin Drug Saf 16(6):651–672

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  121. Sagnelli E, Sagnelli C, Macera M, Pisaturo M, Coppola N (2017) An update on the treatment options for HBV/HCV coinfection. Expert Opin Pharmacother 18(16):1691–1702

    CAS  PubMed  Google Scholar 

  122. European Association for the Study of the Liver (2018) Electronic address eee, European Association for the Study of the L. EASL Recommendations on Treatment of Hepatitis C 2018. J Hepatol 69(2):461–511

    Article  Google Scholar 

  123. Konopnicki D, Mocroft A, de Wit S, Antunes F, Ledergerber B, Katlama C et al (2005) Hepatitis B and HIV: prevalence, AIDS progression, response to highly active antiretroviral therapy and increased mortality in the EuroSIDA cohort. AIDS 19(6):593–601

    Article  PubMed  Google Scholar 

  124. Thio CL (2009) Hepatitis B and human immunodeficiency virus coinfection. Hepatology 49(5 Suppl):S138–S145

    Article  PubMed  Google Scholar 

  125. Gunthard HF, Aberg JA, Eron JJ, Hoy JF, Telenti A, Benson CA et al (2014) Antiretroviral treatment of adult HIV infection: 2014 recommendations of the International Antiviral Society-USA Panel. JAMA 312(4):410–425

    Article  PubMed  CAS  Google Scholar 

  126. Liu F, Wang XW, Chen L, Hu P, Ren H, Hu HD (2016) Systematic review with meta-analysis: development of hepatocellular carcinoma in chronic hepatitis B patients with hepatitis B surface antigen seroclearance. Aliment Pharmacol Ther 43(12):1253–1261

    Article  CAS  PubMed  Google Scholar 

  127. Kim GA, Lee HC, Kim MJ, Ha Y, Park EJ, An J et al (2015) Incidence of hepatocellular carcinoma after HBsAg seroclearance in chronic hepatitis B patients: a need for surveillance. J Hepatol 62(5):1092–1099

    Article  PubMed  Google Scholar 

  128. Wong DK, Seto WK, Cheung KS, Chong CK, Huang FY, Fung J et al (2017) Hepatitis B virus core-related antigen as a surrogate marker for covalently closed circular DNA. Liver Int 37(7):995–1001

    Article  CAS  PubMed  Google Scholar 

  129. Suzuki F, Miyakoshi H, Kobayashi M, Kumada H (2009) Correlation between serum hepatitis B virus core-related antigen and intrahepatic covalently closed circular DNA in chronic hepatitis B patients. J Med Virol 81(1):27–33

    Article  PubMed  CAS  Google Scholar 

  130. Giersch K, Allweiss L, Volz T, Dandri M, Lutgehetmann M (2017) Serum HBV pgRNA as a clinical marker for cccDNA activity. J Hepatol 66(2):460–462

    Article  CAS  PubMed  Google Scholar 

  131. Yan H, Zhong GC, Xu GW, He WH, Jing ZY, Gao ZC et al (2012) Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus. elife 1

    Google Scholar 

  132. Volz T, Allweiss L, Ben MM, Warlich M, Lohse AW, Pollok JM et al (2013) The entry inhibitor Myrcludex-B efficiently blocks intrahepatic virus spreading in humanized mice previously infected with hepatitis B virus. J Hepatol 58(5):861–867

    Article  CAS  PubMed  Google Scholar 

  133. Blank A, Markert C, Hohmann N, Carls A, Mikus G, Lehr T et al (2016) First-in-human application of the novel hepatitis B and hepatitis D virus entry inhibitor myrcludex B. J Hepatol 65(3):483–489

    Article  CAS  PubMed  Google Scholar 

  134. Late-breaking abstracts (2014) Hepatology (Baltimore, MD) 60(6):1267A–1290A

    Article  Google Scholar 

  135. Nkongolo S, Ni Y, Lempp FA, Kaufman C, Lindner T, Esser-Nobis K et al (2014) Cyclosporin A inhibits hepatitis B and hepatitis D virus entry by cyclophilin-independent interference with the NTCP receptor. J Hepatol 60(4):723–731

    Article  CAS  PubMed  Google Scholar 

  136. Watashi K, Sluder A, Daito T, Matsunaga S, Ryo A, Nagamori S et al (2014) Cyclosporin A and its analogs inhibit hepatitis B virus entry into cultured hepatocytes through targeting a membrane transporter, sodium taurocholate cotransporting polypeptide (NTCP). Hepatology (Baltimore, MD) 59(5):1726–1737

    Article  CAS  Google Scholar 

  137. Vaz FM, Paulusma CC, Huidekoper H, de Ru M, Lim C, Koster J et al (2015) Sodium taurocholate cotransporting polypeptide (SLC10A1) deficiency: conjugated hypercholanemia without a clear clinical phenotype. Hepatology (Baltimore, MD) 61(1):260–267

    Article  CAS  Google Scholar 

  138. Shimura S, Watashi K, Fukano K, Peel M, Sluder A, Kawai F et al (2017) Cyclosporin derivatives inhibit hepatitis B virus entry without interfering with NTCP transporter activity. J Hepatol 66(4):685–692

    Article  CAS  PubMed  Google Scholar 

  139. Janahi EM, McGarvey MJ (2013) The inhibition of hepatitis B virus by APOBEC cytidine deaminases. J Viral Hepat 20(12):821–828

    Article  CAS  PubMed  Google Scholar 

  140. Lucifora J, Xia Y, Reisinger F, Zhang K, Stadler D, Cheng X et al (2014) Specific and nonhepatotoxic degradation of nuclear hepatitis B virus cccDNA. Science (New York, NY) 343(6176):1221–1228

    Article  CAS  Google Scholar 

  141. Chen Y, Hu J, Cai X, Huang Y, Zhou X, Tu Z et al (2018) APOBEC3B edits HBV DNA and inhibits HBV replication during reverse transcription. Antivir Res 149:16–25

    Article  CAS  PubMed  Google Scholar 

  142. Koh S, Kah J, Tham CYL, Yang N, Ceccarello E, Chia A et al (2018) Nonlytic Lymphocytes Engineered to Express Virus-Specific T-Cell Receptors Limit HBV Infection by Activating APOBEC3. Gastroenterology 155(1):180–93.e6

    Article  CAS  PubMed  Google Scholar 

  143. Meier MA, Suslov A, Ketterer S, Heim MH, Wieland SF (2017) Hepatitis B virus covalently closed circular DNA homeostasis is independent of the lymphotoxin pathway during chronic HBV infection. J Viral Hepat 24(8):662–671

    Article  CAS  PubMed  Google Scholar 

  144. Gaj T, Gersbach CA, Barbas CF 3rd (2013) ZFN, TALEN, and CRISPR/Cas-based methods for genome engineering. Trends Biotechnol 31(7):397–405

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  145. Sander JD, Joung JK (2014) CRISPR-Cas systems for editing, regulating and targeting genomes. Nat Biotechnol 32(4):347–355

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  146. Schiffer JT, Aubert M, Weber ND, Mintzer E, Stone D, Jerome KR (2012) Targeted DNA mutagenesis for the cure of chronic viral infections. J Virol 86(17):8920–8936

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  147. Joung JK, Sander JD (2013) TALENs: a widely applicable technology for targeted genome editing. Nat Rev Mol Cell Biol 14(1):49–55

    Article  CAS  PubMed  Google Scholar 

  148. Bloom K, Ely A, Mussolino C, Cathomen T, Arbuthnot P (2013) Inactivation of hepatitis B virus replication in cultured cells and in vivo with engineered transcription activator-like effector nucleases. Mol Ther 21(10):1889–1897

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  149. Maeder ML, Thibodeau-Beganny S, Osiak A, Wright DA, Anthony RM, Eichtinger M et al (2008) Rapid "open-source" engineering of customized zinc-finger nucleases for highly efficient gene modification. Mol Cell 31(2):294–301

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  150. Holkers M, Maggio I, Liu J, Janssen JM, Miselli F, Mussolino C et al (2013) Differential integrity of TALE nuclease genes following adenoviral and lentiviral vector gene transfer into human cells. Nucleic Acids Res 41(5):e63

    Article  CAS  PubMed  Google Scholar 

  151. Kennedy EM, Kornepati AV, Cullen BR (2015) Targeting hepatitis B virus cccDNA using CRISPR/Cas9. Antivir Res 123:188–192

    Article  CAS  PubMed  Google Scholar 

  152. Lin SR, Yang HC, Kuo YT, Liu CJ, Yang TY, Sung KC et al (2014) The CRISPR/Cas9 system facilitates clearance of the intrahepatic HBV templates in vivo. Molecular therapy Nucleic acids 3:e186

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  153. Dong C, Qu L, Wang H, Wei L, Dong Y, Xiong S (2015) Targeting hepatitis B virus cccDNA by CRISPR/Cas9 nuclease efficiently inhibits viral replication. Antivir Res 118:110–117

    Article  CAS  PubMed  Google Scholar 

  154. Li H, Sheng C, Wang S, Yang L, Liang Y, Huang Y et al (2017) Removal of integrated hepatitis B virus DNA using CRISPR-Cas9. Front Cell Infect Microbiol 7:91

    PubMed  PubMed Central  Google Scholar 

  155. Li H, Sheng C, Liu H, Wang S, Zhao J, Yang L et al (2018) Inhibition of HBV expression in HBV transgenic mice using AAV-delivered CRISPR-SaCas9. Front Immunol 9:2080

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  156. Kostyushev D, Kostyusheva A, Brezgin S, Zarifyan D, Utkina A, Goptar I et al (2019) Suppressing the NHEJ pathway by DNA-PKcs inhibitor NU7026 prevents degradation of HBV cccDNA cleaved by CRISPR/Cas9. Sci Rep 9(1):1847

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  157. Yang HC, Chen PJ (2018) The potential and challenges of CRISPR-Cas in eradication of hepatitis B virus covalently closed circular DNA. Virus Res 244:304–310

    Article  CAS  PubMed  Google Scholar 

  158. Choi YM, Lee SY, Kim BJ (2019) Naturally occurring hepatitis B virus mutations leading to endoplasmic reticulum stress and their contribution to the progression of hepatocellular carcinoma. Int J Mol Sci 20(3)

    Article  CAS  PubMed Central  Google Scholar 

  159. Sung FY, Lan CY, Huang CJ, Lin CL, Liu CJ, Chen PJ et al (2016) Progressive accumulation of mutations in the hepatitis B virus genome and its impact on time to diagnosis of hepatocellular carcinoma. Hepatology (Baltimore, MD) 64(3):720–731

    Article  CAS  Google Scholar 

  160. Jiang C, Mei M, Li B, Zhu X, Zu W, Tian Y et al (2017) A non-viral CRISPR/Cas9 delivery system for therapeutically targeting HBV DNA and pcsk9 in vivo. Cell Res 27(3):440–443

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  161. Zhang Y, Mao R, Guo H, Zhang J (2017) Detection of HBV cccDNA methylation from clinical samples by bisulfite sequencing and methylation-specific PCR. Methods Mol Biol 1540:73–84

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  162. Wei HS, Dong QM, Zhuang H, Song SJ, Liu ZY, Cheng J (2006) Establishing a fluorescence quantitative polymerase chain reaction for detection of HBV cccDNA in serum. Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology 14(1):56–58

    CAS  PubMed  Google Scholar 

  163. Lucifora J, Salvetti A, Marniquet X, Mailly L, Testoni B, Fusil F et al (2017) Detection of the hepatitis B virus (HBV) covalently-closed-circular DNA (cccDNA) in mice transduced with a recombinant AAV-HBV vector. Antivir Res 145:14–19

    Article  CAS  PubMed  Google Scholar 

  164. Maepa MB, Roelofse I, Ely A, Arbuthnot P (2015) Progress and prospects of anti-HBV gene therapy development. Int J Mol Sci 16(8):17589–17610

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  165. Thi EP, Dhillon AP, Ardzinski A, Bidirici-Ertekin L, Cobarrubias KD, Cuconati A et al (2019) ARB-1740, a RNA interference therapeutic for chronic hepatitis B infection. ACS Infect Dis 5(5):725–737

    Article  CAS  PubMed  Google Scholar 

  166. Gish RG, Yuen MF, Chan HL, Given BD, Lai CL, Locarnini SA et al (2015) Synthetic RNAi triggers and their use in chronic hepatitis B therapies with curative intent. Antivir Res 121:97–108

    Article  CAS  PubMed  Google Scholar 

  167. Brahmania M, Feld J, Arif A, Janssen HL (2016) New therapeutic agents for chronic hepatitis B. Lancet Infect Dis 16(2):e10–e21

    Article  CAS  PubMed  Google Scholar 

  168. McCaffrey AP, Nakai H, Pandey K, Huang Z, Salazar FH, Xu H et al (2003) Inhibition of hepatitis B virus in mice by RNA interference. Nat Biotechnol 21(6):639–644

    Article  CAS  PubMed  Google Scholar 

  169. Wooddell CI, Yuen MF, Chan HL, Gish RG, Locarnini SA, Chavez D et al (2017) RNAi-based treatment of chronically infected patients and chimpanzees reveals that integrated hepatitis B virus DNA is a source of HBsAg. Sci Transl Med 9(409)

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  170. Hamilton J (2018) Overcoming the challenges of RNAi-based therapy: an interview with James Hamilton. Ther Deliv 9(7):511–513

    Article  CAS  PubMed  Google Scholar 

  171. Edward Gane SAL, Lim TH, Simone Strasser WS, Cheng W, Alexander Thompson BG, Schluep T, James Hamilton GC, Wong D, Christian Schwabe KJ, Ferrari C, Ching-Lung Lai RGG, Yuen M-F (2019) RNA interference (RNAi) in chronic hepatitis B (CHB): data from Phase 2 study with JNJ-3989. Hepatol Int 13(Suppl 1):S1–S266

    Google Scholar 

  172. Lee ACH, Thi EP, Cuconati A, Ardzinski A, Holland R, Huang H et al (2019) Function and drug combination studies in cell culture models for AB-729, a subcutaneously administered siRNA investigational agent for chronic hepatitis B infection. J Hepatol 70:E471–E

    Google Scholar 

  173. Peters MG, Locarnini S (2017) New direct-acting antiviral agents and immunomodulators for hepatitis B virus infection. Gastroenterol Hepatol 13(6):348–356

    Google Scholar 

  174. Lam AM, Espiritu C, Vogel R, Ren S, Lau V, Kelly M et al (2019) Preclinical characterization of NVR 3-778, a first-in-class capsid assembly modulator against hepatitis B virus. Antimicrob Agents Chemother 63:1

    Article  CAS  Google Scholar 

  175. Cole AG (2016) Modulators of HBV capsid assembly as an approach to treating hepatitis B virus infection. Curr Opin Pharmacol 30:131–137

    Article  CAS  PubMed  Google Scholar 

  176. Lahlali T, Berke JM, Vergauwen K, Foca A, Vandyck K, Pauwels F et al (2018) Novel potent capsid assembly modulators regulate multiple steps of the hepatitis B virus life cycle. Antimicrob Agents Chemother 62(10)

    Google Scholar 

  177. Berke JM, Dehertogh P, Vergauwen K, van Damme E, Raboisson P, Pauwels F et al (2016) Capsid assembly modulator JNJ-56136379 prevents de novo infection of primary human hepatocytes with hepatitis B virus. Hepatology (Baltimore, MD) 64:124a-a

    Google Scholar 

  178. Berke JM, Dehertogh P, Vergauwen K, Van Damme E, Mostmans W, Vandyck K et al (2017) Capsid assembly modulators have a dual mechanism of action in primary human hepatocytes infected with hepatitis B virus. Antimicrob Agents Chemother 61(8)

    Google Scholar 

  179. Klumpp K, Shimada T, Allweiss L, Volz T, Lutgehetmann M, Hartman G et al (2018) Efficacy of NVR 3-778, alone and in combination with pegylated interferon, vs entecavir in uPA/SCID mice with humanized livers and HBV infection. Gastroenterology 154(3):652–62.e8

    Article  CAS  PubMed  Google Scholar 

  180. Yuen MF, Gane EJ, Kim DJ, Weilert F, Yuen Chan HL, Lalezari J et al (2019) Antiviral activity, safety, and pharmacokinetics of capsid assembly modulator NVR 3-778 in patients with chronic HBV infection. Gastroenterology 156(5):1392–1403.e7

    Article  CAS  PubMed  Google Scholar 

  181. F. Zoulim JZY JJV et al Safety, pharmacokinetics and antiviral activity of a novel hepatitis B virus capsid assembly modulator, JNJ-56136379, in patients with chronic hepatitis B. APASL2019.

    Google Scholar 

  182. Zhang H ZX, Chen H et al Safety, pharmacokinetics and anti-viral efficacy of novel core protein allosteric modifier GLS4 in patients with chronic hepatitis B: interim results from a 48 weeks phase 2a study. AASLD 2018 Abstract LB-13.

    Google Scholar 

  183. Ma XL LJ et al (2019) Interim safety and efficacy results of the ABI-H0731 phase 2a program exploring the combination of ABI-H0731 with Nuc therapy in treatment-naive and treatment-suppressed chronic hepatitis B patients. EASL 2019 Abs LBO-06: Hepatology

    Google Scholar 

  184. Feng S, Gao L, Han X, Hu T, Hu Y, Liu H et al (2018) Discovery of small molecule therapeutics for treatment of chronic HBV infection. ACS Infect Dis 4(3):257–277

    Article  CAS  PubMed  Google Scholar 

  185. Zhang X, Cheng J, Ma J, Hu Z, Wu S, Hwang N et al (2019) Discovery of novel hepatitis B virus nucleocapsid assembly inhibitors. ACS Infect Dis 5(5):759–768

    Article  CAS  PubMed  Google Scholar 

  186. Lai CL, Ahn SH, Lee KS, Um SH, Cho M, Yoon SK et al (2014) Phase IIb multicentred randomised trial of besifovir (LB80380) versus entecavir in Asian patients with chronic hepatitis B. Gut 63(6):996–1004

    Article  CAS  PubMed  Google Scholar 

  187. Ahn SH, Kim W, Jung YK, Yang JM, Jang JY, Kweon YO et al (2019) Efficacy and safety of besifovir dipivoxil maleate compared with tenofovir disoproxil fumarate in treatment of chronic hepatitis B virus infection. Clin Gastroenterol Hepatol 17(9):1850–9.e4

    Article  CAS  PubMed  Google Scholar 

  188. Painter GR, Almond MR, Trost LC, Lampert BM, Neyts J, De Clercq E et al (2007) Evaluation of hexadecyloxypropyl-9-R-[2-(Phosphonomethoxy)propyl]- adenine, CMX157, as a potential treatment for human immunodeficiency virus type 1 and hepatitis B virus infections. Antimicrob Agents Chemother 51(10):3505–3509

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  189. Tavis JE, Lomonosova E (2015) The hepatitis B virus ribonuclease H as a drug target. Antivir Res 118:132–138

    Article  CAS  PubMed  Google Scholar 

  190. Hu Y, Cheng X, Cao F, Huang A, Tavis JE (2013) beta-Thujaplicinol inhibits hepatitis B virus replication by blocking the viral ribonuclease H activity. Antivir Res 99(3):221–229

    Article  CAS  PubMed  Google Scholar 

  191. Cai CW, Lomonosova E, Moran EA, Cheng X, Patel KB, Bailly F et al (2014) Hepatitis B virus replication is blocked by a 2-hydroxyisoquinoline-1,3(2H,4H)-dione (HID) inhibitor of the viral ribonuclease H activity. Antivir Res 108:48–55

    Article  CAS  PubMed  Google Scholar 

  192. Edwards TC, Lomonosova E, Patel JA, Li Q, Villa JA, Gupta AK et al (2017) Inhibition of hepatitis B virus replication by N-hydroxyisoquinolinediones and related polyoxygenated heterocycles. Antivir Res 143:205–217

    Article  CAS  PubMed  Google Scholar 

  193. Blanchet M, Sinnathamby V, Vaillant A, Labonte P (2019) Inhibition of HBsAg secretion by nucleic acid polymers in HepG2.2.15cells. Antivir Res 164:97–105

    Article  CAS  PubMed  Google Scholar 

  194. Bazinet M, Pantea V, Cebotarescu V, Cojuhari L, Jimbei P, Albrecht J et al (2017) Safety and efficacy of REP 2139 and pegylated interferon alfa-2a for treatment-naive patients with chronic hepatitis B virus and hepatitis D virus co-infection (REP 301 and REP 301-LTF): a non-randomised, open-label, phase 2 trial. Lancet Gastroenterol Hepatol 2(12):877–889

    Article  PubMed  Google Scholar 

  195. Al-Mahtab M, Bazinet M, Vaillant A (2016) Safety and efficacy of nucleic acid polymers in monotherapy and combined with immunotherapy in treatment-naive Bangladeshi patients with HBeAg+ chronic hepatitis B infection. PLoS One 11(6):e0156667

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  196. Usman Z, Mijocevic H, Karimzadeh H, Daumer M, Mamun AM, Bazinet M et al (2019) Kinetics of hepatitis B surface antigen quasispecies during REP 2139-Ca therapy in HBeAg positive chronic HBV infection. J Viral Hepat

    Google Scholar 

  197. Vaillant A (2019) REP 2139: antiviral mechanisms and applications in achieving functional control of HBV and HDV infection. ACS Infect Dis 5(5):675–687

    Article  CAS  PubMed  Google Scholar 

  198. Akira S, Takeda K, Kaisho T (2001) Toll-like receptors: critical proteins linking innate and acquired immunity. Nat Immunol 2(8):675–680

    Article  CAS  PubMed  Google Scholar 

  199. Lang T, Lo C, Skinner N, Locarnini S, Visvanathan K, Mansell A (2011) The hepatitis B e antigen (HBeAg) targets and suppresses activation of the toll-like receptor signaling pathway. J Hepatol 55(4):762–769

    Article  CAS  PubMed  Google Scholar 

  200. Rehermann B, Nascimbeni M (2005) Immunology of hepatitis B virus and hepatitis C virus infection. Nat Rev Immunol 5(3):215–229

    Article  CAS  PubMed  Google Scholar 

  201. Jo J, Tan AT, Ussher JE, Sandalova E, Tang XZ, Tan-Garcia A et al (2014) Toll-like receptor 8 agonist and bacteria trigger potent activation of innate immune cells in human liver. PLoS Pathog 10(6):e1004210

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  202. Niu C, Li L, Daffis S, Lucifora J, Bonnin M, Maadadi S et al (2018) Toll-like receptor 7 agonist GS-9620 induces prolonged inhibition of HBV via a type I interferon-dependent mechanism. J Hepatol 68(5):922–931

    Article  CAS  PubMed  Google Scholar 

  203. Menne S, Tumas DB, Liu KH, Thampi L, AlDeghaither D, Baldwin BH et al (2015) Sustained efficacy and seroconversion with the Toll-like receptor 7 agonist GS-9620 in the Woodchuck model of chronic hepatitis B. J Hepatol 62(6):1237–1245

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  204. Lanford RE, Guerra B, Chavez D, Giavedoni L, Hodara VL, Brasky KM, et al. (2013) GS-9620, an oral agonist of Toll-like receptor-7, induces prolonged suppression of hepatitis B virus in chronically infected chimpanzees. Gastroenterology 144(7):1508-17, 1517.e1–10

    Article  CAS  Google Scholar 

  205. Boni C, Vecchi A, Rossi M, Laccabue D, Giuberti T, Alfieri A et al (2018) TLR7 agonist increases responses of hepatitis B virus-specific T cells and natural killer cells in patients with chronic hepatitis B treated with nucleos(T)ide analogues. Gastroenterology 154(6):1764–77.e7

    Article  CAS  PubMed  Google Scholar 

  206. Janssen HLA, Brunetto MR, Kim YJ, Ferrari C, Massetto B, Nguyen AH et al (2018) Safety, efficacy and pharmacodynamics of vesatolimod (GS-9620) in virally suppressed patients with chronic hepatitis B. J Hepatol 68(3):431–440

    Article  CAS  PubMed  Google Scholar 

  207. L. DaiY.YuL.GuJ.ZhaoL.ZhuH.YunY.JiW.ZhuJ.YoungL.Gao. Combination treatment of a TLR7 agonist RO7020531and a capsid assembly modulator RO7049389 achieved sustainable viral load suppression and HBsAg loss in an AAV-HBV mouse model. J Hepatol 2018;68(Supplement 1): S17-SS8.

    Google Scholar 

  208. Andrea Luk JFG, Folitar I, Triyatni M, Glavini K, Zhao L, Upmanyu R, Racek T, Hoppe S, Fok B, Zhu Y, Jin Y, Jiang Q (2019) A single and multiple ascending dose study of Toll-like receptor 7 (TLR 7) agonist (RO7020531) in Chinese healthy subjects. Hepatol Int 13(Suppl 1):s39

    Google Scholar 

  209. Daffis S, Chamberlain J, Zheng J, Santos R, Rowe W, Mish M et al (2017) Sustained efficacy and surface antigen seroconversion in the woodchuck model of chronic hepatitis B with the selective toll-like receptor 8 agonist GS-9688. J Hepatol 66(1):S692–S6S3

    Article  Google Scholar 

  210. Gane EJ, Kim HJ, Visvanathan K, Kim YJ, Nguyen A-H, Reyes M et al (2019) A randomized, placebo-controlled, blinded phase 1b study evaluating the oral TLR8 agonist GS-9688 in patients with chronic hepatitis B (CHB). Hepatol Int 13(Suppl 1):S53

    Google Scholar 

  211. Jones M, Cunningham ME, Wing P, DeSilva S, Challa R, Sheri A et al (2017) SB 9200, a novel agonist of innate immunity, shows potent antiviral activity against resistant HCV variants. J Med Virol 89(9):1620–1628

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  212. Sato S, Li K, Kameyama T, Hayashi T, Ishida Y, Murakami S et al (2015) The RNA sensor RIG-I dually functions as an innate sensor and direct antiviral factor for hepatitis B virus. Immunity 42(1):123–132

    Article  CAS  PubMed  Google Scholar 

  213. Dawood A, Abdul Basit S, Jayaraj M, Gish RG (2017) Drugs in development for hepatitis B. Drugs 77(12):1263–1280

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  214. Macfarlane C, Locarnini S, Jackson K, Walsh R, Edwards R et al (2018) Inarigivir: a novel RIG-I agonist for chronic hepatitis B. Hepatol Int 12(Suppl 2):S264

    Google Scholar 

  215. Yuen M-F, Chen C-Y, Liu C-J, Jeng RW-J, Elkhashab M, Coffin C et al (2019) Ascending dose cohort study of inarigivir – a novel RIG I agonist in chronic HBV patients: final results of the ACHIEVE trial. J Hepatol 70(1 Supplement):e47–ee8

    Article  Google Scholar 

  216. Cho H, Kang H, Lee HH, Kim CW (2017) Programmed cell death 1 (PD-1) and cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) in viral hepatitis. Int J Mol Sci 18(7)

    Article  PubMed Central  CAS  Google Scholar 

  217. Peng G, Li S, Wu W, Tan X, Chen Y, Chen Z (2008) PD-1 upregulation is associated with HBV-specific T cell dysfunction in chronic hepatitis B patients. Mol Immunol 45(4):963–970

    Article  CAS  PubMed  Google Scholar 

  218. Kassel R, Cruise MW, Iezzoni JC, Taylor NA, Pruett TL, Hahn YS (2009) Chronically inflamed livers up-regulate expression of inhibitory B7 family members. Hepatology (Baltimore, MD) 50(5):1625–1637

    Article  Google Scholar 

  219. Zhang WJ, Peng CH, Zheng SS (2013) Programmed death 1 and programmed death ligand 1 expressions in patients with chronic hepatitis B. Hepatobiliary Pancreat Dis Int 12(4):394–399

    Article  CAS  PubMed  Google Scholar 

  220. Barber DL, Wherry EJ, Masopust D, Zhu B, Allison JP, Sharpe AH et al (2006) Restoring function in exhausted CD8 T cells during chronic viral infection. Nature 439(7077):682–687

    Article  CAS  PubMed  Google Scholar 

  221. Fisicaro P, Valdatta C, Massari M, Loggi E, Biasini E, Sacchelli L, et al (2010) Antiviral intrahepatic T-cell responses can be restored by blocking programmed death-1 pathway in chronic hepatitis B. Gastroenterology 138(2):682–93, 693.e1–4.

    Article  CAS  Google Scholar 

  222. Zhang E, Zhang X, Liu J, Wang B, Tian Y, Kosinska AD et al (2011) The expression of PD-1 ligands and their involvement in regulation of T cell functions in acute and chronic woodchuck hepatitis virus infection. PLoS One 6(10):e26196

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  223. Liu J, Zhang E, Ma Z, Wu W, Kosinska A, Zhang X et al (2014) Enhancing virus-specific immunity in vivo by combining therapeutic vaccination and PD-L1 blockade in chronic hepadnaviral infection. PLoS Pathog 10(1):e1003856

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  224. Gane E, Verdon DJ, Brooks AE, Gaggar A, Nguyen AH, Subramanian GM et al (2019) Anti-PD-1 blockade with nivolumab with and without therapeutic vaccination for virally suppressed chronic hepatitis B: a pilot study. J Hepatol

    Google Scholar 

  225. Pagliaccetti NE, Chu EN, Bolen CR, Kleinstein SH, Robek MD (2010) Lambda and alpha interferons inhibit hepatitis B virus replication through a common molecular mechanism but with different in vivo activities. Virology 401(2):197–206

    Article  CAS  PubMed  Google Scholar 

  226. Schurich A, Pallett LJ, Lubowiecki M, Singh HD, Gill US, Kennedy PT et al (2013) The third signal cytokine IL-12 rescues the anti-viral function of exhausted HBV-specific CD8 T cells. PLoS Pathog 9(3):e1003208

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  227. Zeng Z, Kong X, Li F, Wei H, Sun R, Tian Z (2013) IL-12-based vaccination therapy reverses liver-induced systemic tolerance in a mouse model of hepatitis B virus carrier. J Immunol (Baltimore, MD: 1950) 191(8):4184–4193

    Article  CAS  Google Scholar 

  228. Carreno V, Zeuzem S, Hopf U, Marcellin P, Cooksley WG, Fevery J et al (2000) A phase I/II study of recombinant human interleukin-12 in patients with chronic hepatitis B. J Hepatol 32(2):317–324

    Article  CAS  PubMed  Google Scholar 

  229. Tang L, Chen C, Gao X, Zhang W, Yan X, Zhou Y et al (2019) Interleukin 21 reinvigorates the antiviral activity of hepatitis B virus (HBV)-specific CD8+ T cells in chronic HBV infection. J Infect Dis 219(5):750–759

    Article  PubMed  Google Scholar 

  230. Li HJ, Kang FB, Li BS, Yang XY, Zhang YG, Sun DX (2015) Interleukin-21 inhibits HBV replication in vitro. Antivir Ther 20(6):583–590

    Article  CAS  PubMed  Google Scholar 

  231. Tsuge M, Hiraga N, Zhang Y, Yamashita M, Sato O, Oka N et al (2018) Endoplasmic reticulum-mediated induction of interleukin-8 occurs by hepatitis B virus infection and contributes to suppression of interferon responsiveness in human hepatocytes. Virology 525:48–61

    Article  CAS  PubMed  Google Scholar 

  232. Lobaina Y, Michel ML (2017) Chronic hepatitis B: immunological profile and current therapeutic vaccines in clinical trials. Vaccine 35(18):2308–2314

    Article  CAS  PubMed  Google Scholar 

  233. Kosinska AD, Bauer T, Protzer U (2017) Therapeutic vaccination for chronic hepatitis B. Curr Opin Virol 23:75–81

    Article  CAS  PubMed  Google Scholar 

  234. Dembek C, Protzer U, Roggendorf M (2018) Overcoming immune tolerance in chronic hepatitis B by therapeutic vaccination. Curr Opin Virol 30:58–67

    Article  CAS  PubMed  Google Scholar 

  235. Vandepapeliere P, Lau GK, Leroux-Roels G, Horsmans Y, Gane E, Tawandee T et al (2007) Therapeutic vaccination of chronic hepatitis B patients with virus suppression by antiviral therapy: a randomized, controlled study of co-administration of HBsAg/AS02 candidate vaccine and lamivudine. Vaccine 25(51):8585–8597

    Article  CAS  PubMed  Google Scholar 

  236. Lobaina Y, Palenzuela D, Pichardo D, Muzio V, Guillen G, Aguilar JC (2005) Immunological characterization of two hepatitis B core antigen variants and their immunoenhancing effect on co-delivered hepatitis B surface antigen. Mol Immunol 42(3):289–294

    Article  CAS  PubMed  Google Scholar 

  237. Fernandez G, A LS, Jerez E, L EA, Freyre F, J AA et al (2018) Five-year follow-up of chronic hepatitis B patients immunized by nasal route with the therapeutic vaccine HeberNasvac. Euro J Hepato-Gastroenterol 8(2):133–139

    Article  Google Scholar 

  238. Xu DZ, Huang KL, Zhao K, Xu LF, Shi N, Yuan ZH et al (2005) Vaccination with recombinant HBsAg-HBIG complex in healthy adults. Vaccine 23(20):2658–2664

    Article  CAS  PubMed  Google Scholar 

  239. Xu DZ, Wang XY, Shen XL, Gong GZ, Ren H, Guo LM et al (2013) Results of a phase III clinical trial with an HBsAg-HBIG immunogenic complex therapeutic vaccine for chronic hepatitis B patients: experiences and findings. J Hepatol 59(3):450–456

    Article  CAS  PubMed  Google Scholar 

  240. Obeng-Adjei N, Hutnick NA, Yan J, Chu JS, Myles DJ, Morrow MP et al (2013) DNA vaccine cocktail expressing genotype A and C HBV surface and consensus core antigens generates robust cytotoxic and antibody responses in mice and Rhesus macaques. Cancer Gene Ther 20(12):652–662

    Article  CAS  PubMed  Google Scholar 

  241. Yoon SK, Seo YB, Im SJ, Bae SH, Song MJ, You CR et al (2015) Safety and immunogenicity of therapeutic DNA vaccine with antiviral drug in chronic HBV patients and its immunogenicity in mice. Liver Int 35(3):805–815

    Article  CAS  PubMed  Google Scholar 

  242. Boni C, Janssen HLA, Rossi M, Yoon SK, Vecchi A, Barili V et al (2019) Combined GS-4774 and tenofovir therapy can improve HBV-specific T-cell responses in patients with chronic hepatitis. Gastroenterology 157(1):227–41.e7

    Article  CAS  PubMed  Google Scholar 

  243. Lok AS, Pan CQ, Han SH, Trinh HN, Fessel WJ, Rodell T et al (2016) Randomized phase II study of GS-4774 as a therapeutic vaccine in virally suppressed patients with chronic hepatitis B. J Hepatol 65(3):509–516

    Article  CAS  PubMed  Google Scholar 

  244. Martin P, Dubois C, Jacquier E, Dion S, Mancini-Bourgine M, Godon O et al (2015) TG1050, an immunotherapeutic to treat chronic hepatitis B, induces robust T cells and exerts an antiviral effect in HBV-persistent mice. Gut 64(12):1961–1971

    Article  CAS  PubMed  Google Scholar 

  245. Zoulim F, Fournier C, Habersetzer F, Sprinzl M, Pol S, Coffin CS et al (2019) Safety and immunogenicity of the therapeutic vaccine TG1050 in chronic hepatitis B Patients: a phase 1b placebo-controlled trial. Hum Vaccin Immunother. https://doi.org/10.1080/21645515.2019.1651141

Download references

Acknowledgments

This work was supported by a grant from the National Scientific and Technological Major Project for Infectious Diseases Control in China (No.2018ZX10715-003); and a grant from the Key Research and Development Program of Science and Technology Department of Sichuan Province, China (2019YFS0028).

Author information

Author notes

  1. Yachao Tao and Dongbo Wu contributed equally to this chapter

Authors and Affiliations

  1. Center of Infectious Diseases, Division of Infectious Diseases, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, Sichuan, China

    Yachao Tao, Dongbo Wu, Lingyun Zhou, Enqiang Chen, Changhai Liu, Xiaoqiong Tang, Wei Jiang, Ning Han, Hong Li & Hong Tang

Authors
  1. Yachao Tao
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Dongbo Wu
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Lingyun Zhou
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Enqiang Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Changhai Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Xiaoqiong Tang
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Wei Jiang
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Ning Han
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Hong Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Hong Tang
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Center of Infectious Diseases, Division of Infectious Diseases, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, Sichuan, China

    Hong Tang

Rights and permissions

Reprints and permissions

Copyright information

© 2020 Springer Nature Singapore Pte Ltd.

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Tao, Y. et al. (2020). Present and Future Therapies for Chronic Hepatitis B. In: Tang, H. (eds) Hepatitis B Virus Infection. Advances in Experimental Medicine and Biology, vol 1179. Springer, Singapore. https://doi.org/10.1007/978-981-13-9151-4_6

Download citation

Publish with us

Policies and ethics

Search

Navigation